ConductScience.org, home

Paper24252885

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Green NS and 1 other. Pediatr Res, 2014. Cited by 54 papers, by iCite.

Cite this record

ConductScience Library. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Papers, record 24252885. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24252885

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
PubMed
Journal
Pediatr Res
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
2.11
iCite
Revised in PubMed
2021-10-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Green NSNancy S
2Barral SSandra

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anemia, Sickle CellMajor topic
Antisickling AgentsMajor topic
HydroxyureaMajor topic
Age Factors
Animals
Child
Child, Preschool
Fetal Hemoglobin
Genetic Markers
Genetic Predisposition to Disease
Humans
Infant
Infant, Newborn
Phenotype
Polymorphism, Single Nucleotide
Risk Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
UL1 RR024156NCRR NIH HHSUnited StatesUL1RR024156PubMed and NIH
5UL1RR024156NCRR NIH HHSUnited StatesUL1RR024156PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16200161Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?Blood1984https://conductscience.org/library/papers/6200161PubMed
223861242
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Am J Hematol2013https://conductscience.org/library/papers/23861242PubMed
321921042Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.Blood2011https://conductscience.org/library/papers/21921042PubMed
422517797Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.Pediatr Blood Cancer2012https://conductscience.org/library/papers/22517797PubMed
522130804Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.Blood2012https://conductscience.org/library/papers/22130804PubMed
621157349Update on fetal hemoglobin gene regulation in hemoglobinopathies.Curr Opin Pediatr2011https://conductscience.org/library/papers/21157349PubMed
721372708Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Curr Opin Hematol2011https://conductscience.org/library/papers/21372708PubMed
822833547Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.Blood2012https://conductscience.org/library/papers/22833547PubMed
917313560Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.Eur J Haematol2007https://conductscience.org/library/papers/17313560PubMed
1021068435Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort.Blood2011https://conductscience.org/library/papers/21068435PubMed
1120513116The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.Am J Hematol2010https://conductscience.org/library/papers/20513116PubMed
1223125209Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications.Am J Physiol Heart Circ Physiol2013https://conductscience.org/library/papers/23125209PubMed
138822914Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.Blood1996https://conductscience.org/library/papers/8822914PubMed
1420230905Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.Mutat Res2010https://conductscience.org/library/papers/20230905PubMed
1521057501Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation.Nat Genet2010https://conductscience.org/library/papers/21057501PubMed
1622294512Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.Pediatr Blood Cancer2012https://conductscience.org/library/papers/22294512PubMed
1717993617Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.Blood2008https://conductscience.org/library/papers/17993617PubMed
1819914165Nonoptimal microbial response to antibiotics underlies suppressive drug interactions.Cell2009https://conductscience.org/library/papers/19914165PubMed
192001460The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients.Blood1991https://conductscience.org/library/papers/2001460PubMed
203539223Subunit assembly of hemoglobin: an important determinant of hematologic phenotype.Blood1987https://conductscience.org/library/papers/3539223PubMed

See all 81 referencesDownload CSV of references

Cited by40

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
41375813When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease.J Clin Med2025https://conductscience.org/library/papers/41375813PubMed
40868933Role of OCT1 and MAP3K5 Genetic Polymorphisms in Hydroxyurea Pharmacokinetics.Life (Basel)2025https://conductscience.org/library/papers/40868933PubMed
40268903Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Pharmacogenomics J2025https://conductscience.org/library/papers/40268903PubMed
39695103Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice.Cell Death Dis2024https://conductscience.org/library/papers/39695103PubMed
39624343A Comparative Analysis of Hydroxyurea Treatment on Coagulation Profile Among Sickle Cell Anaemia Children in Lagos, Nigeria.Adv Hematol2024https://conductscience.org/library/papers/39624343PubMed
39552261Impact of hydroxycarbamide treatment on the whole-blood transcriptome in sickle cell disease.Br J Haematol2025https://conductscience.org/library/papers/39552261PubMed
39487201Computational screening of phytochemicals present in some Nigerian medicinal plants against sickle cell disease.Sci Rep2024https://conductscience.org/library/papers/39487201PubMed
39359845Advancing life: innovative approaches to enhance survival in sickle cell anemia patients.Ann Med Surg (Lond)2024https://conductscience.org/library/papers/39359845PubMed
39211422Effects of Hydroxyurea Treatment on Haemolysis in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania.Tanzan J Sci2021https://conductscience.org/library/papers/39211422PubMed
39026269Towards genomic medicine: a tailored next-generation sequencing panel for hydroxyurea pharmacogenomics in Tanzania.BMC Med Genomics2024https://conductscience.org/library/papers/39026269PubMed
37269388Sickle cell disease and acute leukemia: one case report and an extensive review.Ann Hematol2023https://conductscience.org/library/papers/37269388PubMed
36060689Sickle cell cerebrovascular reactivity to a CO2 stimulus: Too little, too slow.Front Physiol2022https://conductscience.org/library/papers/36060689PubMed
36047926Hydroxyurea (hydroxycarbamide) for sickle cell disease.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/36047926PubMed
35784862Effects of Hydroxyurea on Skeletal Muscle Energetics and Function in a Mildly Anemic Mouse Model.Front Physiol2022https://conductscience.org/library/papers/35784862PubMed
34857507
Guidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: Associação Médica Brasileira - 2021.
Hematol Transfus Cell Ther2022https://conductscience.org/library/papers/34857507PubMed
34090531Genome-based therapeutic interventions for β-type hemoglobinopathies.Hum Genomics2021https://conductscience.org/library/papers/34090531PubMed
33936317Laser tweezers as a biophotonic tool to investigate the efficacy of living sickle red blood cells in response to optical deformation.Biophys Rev2021https://conductscience.org/library/papers/33936317PubMed
33567814Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.Haematologica2022https://conductscience.org/library/papers/33567814PubMed
32563256High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte.BMC Pediatr2020https://conductscience.org/library/papers/32563256PubMed
32461799Hemoglobinopathies in Iran: An Updated Review.Int J Hematol Oncol Stem Cell Res2020https://conductscience.org/library/papers/32461799PubMed

See all 40 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24252885

GET https://conductscience.org/api/papers/v1/24252885/references?page=2